Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation
- PMID: 17230507
- DOI: 10.1002/ijc.22531
Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation
Abstract
Metastasis continues to be the major cause of morbidity and mortality in malignant melanoma. In our study, we explored whether inhibition of VEGFR-1 or VEGFR-2 signaling conveys distinct suppressive effects on B16 melanoma subcutaneous growth and metastasis formation. The inhibition of VEGFR-1 or -2 alone had no significant influence on both melanoma growth and metastasis formation. In contrast, simultaneous blockade of VEGFR-1 and -2 signaling strongly suppressed progression in both B16 tumor models. There was no expression of VEGFR-1 or -2 detectable on the B16 cells used, excluding the melanoma cells as direct therapeutic targets. Analyzing the contribution of progenitor-like cells during melanoma metastasis formation, we observed an enhanced proliferation and mobilization of VEGFR-1+ myeloid and VEGFR-2+ endothelial cells with progenitor potential by the induction of melanoma lung metastasis, which was not influenced by interference with VEGFR signaling. These results indicate that the antimetastatic effects exerted by combined inhibition of VEGFR-1 and -2 signaling were mediated via targeting cell populations other than progenitors only. Sole inhibition of VEGFR-1 signaling led to a strong reduction of the CD45-positive inflammatory infiltrate in the tumor tissue. However, the formation of lung metastasis was not affected, indicating that inhibition of the inflammatory response was not sufficient to efficiently block B16 melanoma metastasis development. Taken together, our data suggest that in the utilized B16 tumor models the blockade of both the inflammatory and the VEGFR-2-dependent angiogenic response are necessary to effectively inhibit solid tumor growth and formation of lung metastasis by B16 melanoma cells.
(c) 2007 Wiley-Liss, Inc.
Similar articles
-
Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.Cancer Res. 2008 Mar 1;68(5):1581-92. doi: 10.1158/0008-5472.CAN-06-4685. Cancer Res. 2008. PMID: 18316624
-
Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells.Cancer Res. 2011 Nov 15;71(22):6976-85. doi: 10.1158/0008-5472.CAN-11-0627. Epub 2011 Oct 5. Cancer Res. 2011. PMID: 21975929
-
A KDR-binding peptide (ST100,059) can block angiogenesis, melanoma tumor growth and metastasis in vitro and in vivo.Int J Oncol. 2011 Aug;39(2):401-8. doi: 10.3892/ijo.2011.1040. Epub 2011 May 11. Int J Oncol. 2011. PMID: 21567086
-
Prostacyclin and its analogues: antimetastatic effects and mechanisms of action.Cancer Metastasis Rev. 1994 Dec;13(3-4):349-64. doi: 10.1007/BF00666104. Cancer Metastasis Rev. 1994. PMID: 7712596 Review.
-
Rodent models of brain metastasis in melanoma.Melanoma Res. 2005 Oct;15(5):325-56. doi: 10.1097/00008390-200510000-00002. Melanoma Res. 2005. PMID: 16179861 Review.
Cited by
-
Combining Bevacizumab with Radiation or Chemoradiation for Solid Tumors: A Review of the Scientific Rationale, and Clinical Trials.Curr Angiogenes. 2012 Sep;1(3):169-179. doi: 10.2174/2211552811201030169. Curr Angiogenes. 2012. PMID: 24977113 Free PMC article.
-
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models.Mol Cancer Ther. 2009 Oct;8(10):2872-81. doi: 10.1158/1535-7163.MCT-09-0583. Mol Cancer Ther. 2009. PMID: 19825805 Free PMC article.
-
Targeting signaling pathways of VEGFR1 and VEGFR2 as a potential target in the treatment of breast cancer.Mol Biol Rep. 2020 Mar;47(3):2061-2071. doi: 10.1007/s11033-020-05306-9. Epub 2020 Feb 18. Mol Biol Rep. 2020. PMID: 32072404
-
Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells.Yonsei Med J. 2013 Mar 1;54(2):374-80. doi: 10.3349/ymj.2013.54.2.374. Yonsei Med J. 2013. PMID: 23364970 Free PMC article.
-
Exogenous norepinephrine attenuates the efficacy of sunitinib in a mouse cancer model.J Exp Clin Cancer Res. 2014 Feb 20;33(1):21. doi: 10.1186/1756-9966-33-21. J Exp Clin Cancer Res. 2014. PMID: 24555849 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous